The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Open accessAbstract
BACKGROUND: Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly progress to glioblastoma. The uncertainty is compounded by interobserver variability in histologic diagnosis. Mutations in IDH, TP53, and ATRX and codeletion of chromosome arms 1p and 19q (1p/19q codeletion) have been implicated as clinically relevant markers of lower-grade gliomas. METHODS: We performed genomewide analyses of 293 lower-grade gliomas from adults, incorporating exome sequence, DNA copy number, DNA methylation, messenger RNA expression, microRNA expression, and targeted protein expression. These data were integrated and tested for correlation with clinical outcomes. RESULTS: Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. CONCLUSIONS: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class. Lower-grade gliomas with an IDH mutation either had 1p/19q codeletion or carried a TP53 mutation. Most lower-grade gliomas without an IDH mutation were molecularly and clinically similar to glioblastoma. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas1,2.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our patient’s tumor harbored mutations in TERT, FUBP1, and CIC, which are common alterations in oligodendroglioma, but not clinically relevant [46,47].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredIn the citing paper
“IDH WT astrocytomas are, for the most part, highly aggressive, having a median survival of 18 mo”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“Second, predicted risks are consistent with the published expected overall survivals associated with molecular subtypes (37).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“and these have the lowest overall predicted risks consistent with overall survivals of 10+ y (37, 39).”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“IDH mutant astrocytomas are another subtype with considerably better overall survival ranging from 3 to 8 y”
From Predicting cancer outcomes from histology and genomics using convolutional networks (2018) · cites this paper as [37]
In the citing paper
“In recent years, two landmark genomic studies carried out in human glioma and acute myeloid leukaemia (AML) found mutations in IDH1/2 and it is now appreciated that these enzymes (which drive elevated production of D-2-HG) are the most frequently mutated metabolic genes in human cancer112-114.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
Ostrom, Q. T., Gittleman, H. R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz‐Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 12,063
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
The Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,706
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Glioma Groups Based on 1p/19q, IDH , and TERT Promoter Mutations in Tumors
Eckel‐Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M., Smirnov, I. V., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407279 · Cited by 1,981
Flagged first, then by citations
1 of the 54 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Parker BC, 2013, J Clin Invest, 123, 855
Cited by
Sorted by citations
Items 501–600 of 1,002
Ma, S., Rudra, S. F., Campian, J. L., Dahiya, S. M., Dunn, G. P., Johanns, T. M., Goldstein, M., Kim, A. H., & Huang, J. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa126 · Cited by 65
Pei, L., Jones, K. A., Shboul, Z. A., Chen, J. Y., & Iftekharuddin, K. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668694 · Cited by 64
Strong, M. J., Blanchard, E., Lin, Z. N., Morris, C. A., Baddoo, M., Taylor, C. M., Ware, M. L., & Flemington, E. K. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0338-z · Cited by 64
Hu, J. L., Western, S., & Kesari, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00180 · Cited by 66
IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas
Darlix, A., Deverdun, J., de Champfleur, N. M., Castan, F., Zouaoui, S., Rigau, V., Fabbro, M., Yordanova, Y. N., Bars, E. L., Bauchet, L., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2421-0 · Cited by 64
Physical and Molecular Landscapes of Mouse Glioma Extracellular Vesicles Define Heterogeneity
Gyuris, A., Navarrete-Perea, J., Jo, A., Cristea, S., Zhou, S., Fraser, K. B., Wei, Z., Krichevsky, A. M., Weissleder, R., Lee, H., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.089 · Cited by 64
Wen, Z., Zeng, W., Chen, Y., He, L., Wang, J., Cheng, Q., Yu, J., Zhou, H., Liu, Z.-Z., Xiao, J., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1287-8 · Cited by 64
Lucas, C.-H. G., Gupta, R. K., Doo, P., Lee, J. C., Cadwell, C. R., Ramani, B., Hofmann, J. W., Sloan, E. A., Kleinschmidt-DeMasters, B. K., Lee, H. S., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01027-z · Cited by 64
High Expression of Glycolytic Genes in Clinical Glioblastoma Patients Correlates With Lower Survival
Stanke, K. M., Wilson, C., & Kidambi, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.752404 · Cited by 64
Rajendran, S. H., Hu, Y., Canella, A., Peterson, C. R., Gross, A. C., Cam, M., Nazzaro, M., Haffey, A., Harmancı, A. S., Distefano, R., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112197 · Cited by 63
Yang, Z., Liu, X., Xu, H., Teschendorff, A. E., Xu, L., Li, J., Fu, M., Liu, J., Zhou, H., Wang, Y., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06488-9 · Cited by 71
Zhang, L., Kundu, S., Feenstra, T., Li, X., Jin, C., Laaniste, L., Hassan, T. E. A. E., Ohlin, K. E., Yu, D., Olofsson, T., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aaa1690 · Cited by 63
A prospective study of serum metabolites and glioma risk
Huang, J., Weinstein, S. J., Kitahara, C. M., Karoly, E. D., Sampson, J. N., & Albanes, D. (2017) · Oncotarget · doi:10.18632/oncotarget.19705 · Cited by 63
HOX gene cluster (de)regulation in brain: from neurodevelopment to malignant glial tumours
Gonçalves, C. S., Boiteux, E. L., Arnaúd, P., & Costa, B. M. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03508-9 · Cited by 63
Zápotocký, M., Ramaswamy, V., Lassaletta, Á., & Bouffet, É. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26861 · Cited by 64
Deng, X., Lin, D., Zhang, X., Shen, X., Yang, Z., Yang, L., Lu, X., Yu, L., Zhang, N., & Lin, J. J. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29633 · Cited by 62
Universal encoding of pan-cancer histology by deep texture representations
Komura, D., Kawabe, A., Fukuta, K., Sano, K., Umezaki, T., Koda, H., Suzuki, R. H., Tominaga, K., Ochi, M., Konishi, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110424 · Cited by 69
Roles of Notch Signaling in the Tumor Microenvironment
D’Assoro, A. B., Leon-Ferre, R. A., Braune, E.-B., & Lendahl, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116241 · Cited by 63
Xiao, D., Huang, J. X., Pan, Y., Li, H. R., Fu, C., Mao, C., Cheng, Y., Shi, Y., Chen, L., Jiang, Y., et al. (2016) · Theranostics · doi:10.7150/thno.17032 · Cited by 62
Vuong, H. G., Altibi, A. M. A., Duong, U. N. P., Ngo, H. T. T., Pham, T. Q., Chan, A. K., Park, C., Fung, K.-M. A., & Hassell, L. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.013 · Cited by 63
Satomi, K., Ohno, M., Matsushita, Y., Takahashi, M., Miyakita, Y., Narita, Y., Ichimura, K., & Yoshida, A. (2020) · Modern Pathology · doi:10.1038/s41379-020-00701-w · Cited by 65
Chaddad, A., Daniel, P. M., Sabri, S., Desrosiers, C., & Abdulkarim, B. (2019) · Cancers · doi:10.3390/cancers11081148 · Cited by 61
Extent of resection and survival for oligodendroglioma: a U.S. population-based study
Kinslow, C. J., Garton, A. L. A., Rae, A. I., Marcus, L. P., Adams, C. M., McKhann, G. M., Sisti, M. B., Connolly, E. S., Bruce, J. N., Neugut, A. I., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03261-5 · Cited by 61
Barekatain, Y., Ackroyd, J. J., Yan, V. C., Khadka, S., Wang, L., Chen, K., Poral, A. H., Tran, T. T., Georgiou, D. K., Arthur, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24240-3 · Cited by 63
PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients
Draaisma, K., Wijnenga, M. M. J., Weenink, B., Gao, Y., Smid, M., Robe, P. A. J. T., van den Bent, M. J., & French, P. J. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0265-4 · Cited by 61
Radiomic features predict Ki-67 expression level and survival in lower grade gliomas
Li, Y., Qian, Z., Xu, K., Wang, K., Fan, X., Li, S., Liu, X., Wang, Y., & Jiang, T. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2576-8 · Cited by 61
A pan-cancer analysis of prognostic genes
Anaya, J., Reon, B. J., Chen, W., Bekiranov, S., & Dutta, A. (2016) · PeerJ · doi:10.7717/peerj.1499 · Cited by 62
Ginet, M., Zaragori, T., Marie, P., Roch, V., Gauchotte, G., Rech, F., Blonski, M., Lamiral, Z., Taillandier, L., Imbert, L., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04509-y · Cited by 61
VRK1 is a synthetic-lethal target in VRK2-deficient glioblastoma
Shields, J. A., Meier, S. R., Bandi, M., Mulkearns-Hubert, E. E., Hajdari, N., Ferdinez, M. D., Engel, J. L., Silver, D. J., Shen, B., Zhang, W., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4443 · Cited by 60
Du, J., Hou, K., Mi, S., Ji, H., Ma, S., Ba, Y., Hu, S., Xie, R., & Chen, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00208 · Cited by 60
Machine learning analysis of TCGA cancer data
Liñares-Blanco, J., Pazos, A., & Fernandez-Lozano, C. (2021) · PeerJ Computer Science · doi:10.7717/peerj-cs.584 · Cited by 63
Zhang, C., Liu, S., Yuan, X., Hu, Z., Li, H., Wu, M., Yuan, J., Zhao, Z., Su, J., Wang, X., et al. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447912 · Cited by 60
Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor
Alvarez-Breckenridge, C. A., Miller, J. J., Nayyar, N., Gill, C. M., Kaneb, A., D’Andrea, M. R., Le, L. P., Lee, J., Cheng, J., Zheng, Z., et al. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0009-y · Cited by 60
The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities
Srivastava, S., Ghosh, S., Kagan, J., Mazurchuk, R. V., Boja, E. S., Chuaqui, R. F., Chavarria-Johnson, E., Davidsen, T. M., Eary, J. F., Haim, T., et al. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.06.007 · Cited by 60
Accelerated progression of IDH mutant glioma after first recurrence
Miller, J. J., Loebel, F., Juratli, T. A., Tummala, S. S., Williams, E. A., Batchelor, T. T., Arrillaga‐Romany, I., & Cahill, D. P. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz016 · Cited by 62
Batsios, G., Viswanath, P., Subramani, E., Najac, C., Gillespie, A. M., Santos, R. D., Molloy, A. R., Pieper, R. O., & Ronen, S. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47021-x · Cited by 63
Dwyer, D., Kalman, J. L., Budde, M., Kambeitz, J. P., Ruef, A., Antonucci, L. A., Kambeitz‐Ilankovic, L., Hasan, A., Kondofersky, I., Anderson‐Schmidt, H., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4910 · Cited by 64
Muddabhaktuni, B. M. C., & Koyyala, V. P. B. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1735440 · Cited by 59
Updates on the WHO diagnosis of IDH-mutant glioma
Reuß, D. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04250-5 · Cited by 59
Batısta, R., Cruvinel‐Carloni, A., Vinagre, J., Peixoto, J., Catarino, T. A., Campanella, N. C., de Menezes, W. P., Becker, A. P., de Almeida, G. C., Matsushita, M., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30057 · Cited by 60
IDH mutation is associated with higher risk of malignant transformation in low-grade glioma
Leu, S., von Felten, S., Frank, S., Boulay, J., & Mariani, L. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-2048-y · Cited by 59
Quantitative glioma grading using transformed gray-scale invariant textures of MRI
Hsieh, K. L., Chen, C., & Lo, C. (2017) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2017.02.012 · Cited by 59
Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity
Wallmann, T., Zhang, X., Wallerius, M., Bolin, S., Joly, A.-L., Sobocki, C., Leiss, L. W., Jiang, Y., Bergh, J. C. S., Holland, E. C., et al. (2018) · iScience · doi:10.1016/j.isci.2018.10.011 · Cited by 59
Nejo, T., Yamamichi, A., Almeida, N. D., Goretsky, Y. E., & Okada, H. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101385 · Cited by 60
Prediction of Molecular Mutations in Diffuse Low-Grade Gliomas using MR Imaging Features
Shboul, Z. A., Chen, J. Y., & Iftekharuddin, K. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-60550-0 · Cited by 60
Cellular Plasticity and Tumor Microenvironment in Gliomas: The Struggle to Hit a Moving Target
Gargini, R., Segura‐Collar, B., & Sánchez‐Gómez, P. (2020) · Cancers · doi:10.3390/cancers12061622 · Cited by 60
SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II–III Diffuse Gliomas
Zhang, Y.-A., Zhou, Y., Luo, X., Song, K., Ma, X., Sathe, A. A., Girard, L., Xiao, G., & Gazdar, A. F. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.040 · Cited by 58
Cai, J., Hu, Y., Ye, Z., Ye, L., Gao, L., Wang, Y., Sun, Q., Tong, S., Yang, J., & Chen, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1011757 · Cited by 58
Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations
Roy, D. M., Walsh, L. A., Desrichard, A., Huse, J. T., Wu, W., Gao, J., Bose, P., Lee, W., & Chan, T. A.-T. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.025 · Cited by 58
Improvement in cognitive function after surgery for low-grade glioma
Barzilai, O., Moshe, S. B., Sitt, R., Sela, G., Shofty, B., & Ram, Z. (2018) · Journal of neurosurgery · doi:10.3171/2017.9.jns17658 · Cited by 58
Dworkin, M., Mehan, W. A., Niemierko, A., Kamran, S. C., Lamba, N., Dietrich, J., Martinez‐Lage, M., Oh, K. S., Batchelor, T. T., Wen, P. Y., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03063-1 · Cited by 58
Ruiz‐Rodado, V., Malta, T. M., Seki, T., Lita, A., Dowdy, T., Celiku, O., Saldana, A. C., Li, A., Liu, Y., Han, S., et al. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz207 · Cited by 58
Molecular subtyping reveals immune alterations in IDH wild‐type lower‐grade diffuse glioma
Wu, F., Li, G., Liu, H., Zhao, Z., Chai, R., Liu, Y., Jiang, H., Zhai, Y., Feng, Y., Li, R., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5468 · Cited by 57
Faisal, S. M., Comba, A., Varela, M. L., Argento, A. E., Brumley, E. K., Abel, C. C., Castro, M. G., & Lowenstein, P. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005069 · Cited by 58
Захарова, Г. С., Efimov, V., Raevskiy, M., Rumyantsev, P. O., Gudkov, A., Belogurova-Ovchinnikova, O. Y., Sorokin, M., & Buzdin, A. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010157 · Cited by 57
Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma
Peshoff, M., Gupta, P., Oberai, S., Trivedi, R., Katayama, H. G., Chakrapani, P., Dang, M., Migliozzi, S., Gumin, J., Kadri, D. B., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noad257 · Cited by 62
Progress in the application of molecular biomarkers in gliomas
Wang, J., Su, H.-K., Zhao, H., Chen, Z.-P., & To, S. S. T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.148 · Cited by 59
Ding, X., Wang, Z., Chen, D., Wang, Y., Zhao, Z., Sun, C., Chen, D., Tang, C., Xiong, J., Chen, L., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2985-3 · Cited by 57
Surgical management of lower-grade glioma in the spotlight of the 2016 WHO classification system
Delev, D., Heiland, D. H., Franco, P., Reinacher, P. C., Mader, I., Staszewski, O., Laßmann, S., Grau, S., & Schnell, O. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03030-w · Cited by 57
Diffuse low-grade glioma – Changing concepts in diagnosis and management: A review
Jooma, R., Waqas, M. S., & Khan, I. (2019) · Asian Journal of Neurosurgery · doi:10.4103/ajns.ajns_24_18 · Cited by 57
Liu, Y., Chai, R., Wang, Y., Wang, Z., Liu, X., Wu, F., & Jiang, T. (2018) · Cancer Science · doi:10.1111/cas.13878 · Cited by 56
Kinslow, C. J., Mercurio, A. C., Kumar, P., Rae, A. I., Siegelin, M. D., Grinband, J., Taparra, K., Upadhyayula, P. S., McKhann, G. M., Sisti, M. B., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.0990 · Cited by 56
Leblanc, V., & Marra, M. A. (2015) · Cancers · doi:10.3390/cancers7030869 · Cited by 57
Eseonu, C. I., Eguia, F. A., ReFaey, K., García, Ó., Rodríguez, F. J., Chaichana, K. L., & Quiñones‐Hinojosa, A. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2486-9 · Cited by 56
Ono, T., Shirahata, M., Louis, D. N., & von Deimling, A. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1636430 · Cited by 58
Identification of relevant genetic alterations in cancer using topological data analysis
Rabadán, R., Mohamedi, Y., Rubin, U., Chu, T., Alghalith, A. N., Elliott, O., Arnes, L., Cal, S., Obaya, Á. J., Levine, A. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17659-7 · Cited by 56
Metabolic regulation in the immune response to cancer
Wu, Q., Yu, X., Li, J., Sun, S., & Tu, Y. (2021) · 癌症：英文版 · doi:10.1002/cac2.12182 · Cited by 57
Insights From Molecular Profiling of Adult Glioma
Diamandis, P., & Aldape, K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9516 · Cited by 55
Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts
Galbraith, K., Kumar, V., Abdullah, K. G., Walker, J. M., Adams, S. H., Prior, T., Dimentberg, R., Henderson, F. C., Mirchia, K., Sathe, A. A., et al. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa059 · Cited by 55
Franceschi, E., Tosoni, A., Bartolini, S., Minichillo, S., Mura, A., Asioli, S., Bartolini, D., Gardiman, M. P., Gessi, M., Ghimenton, C., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.018 · Cited by 55
Notch signaling in cancer: Complexity and challenges on the path to clinical translation
Ferreira, A. P. A., & Aster, J. C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.008 · Cited by 56
Wang, X., Zhu, W., Wang, Z., Huang, J.-B., Wang, S., Bai, F., Li, T., Zhu, Y., Zhao, J., Yang, X., et al. (2021) · Theranostics · doi:10.7150/thno.63417 · Cited by 56
Ohba, S., Mukherjee, J., Johannessen, T.-C. A., Mancini, A., Chow, T. T., Wood, M. D., Jones, L. E., Mazor, T., Marshall, R. E., Viswanath, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0696 · Cited by 55
Huang, R. Y., Young, R. J., Ellingson, B. M., Veeraraghavan, H., Wang, W., Tixier, F., Um, H., Nawaz, R., Luks, T. L., Kim, J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa105 · Cited by 55
Quantitative texture analysis in the prediction of IDH status in low-grade gliomas
Jakola, A. S., Zhang, Y., Skjulsvik, A. J., Solheim, O. S., Bø, H. K., Berntsen, E. M., Reinertsen, I., Gulati, S., Förander, P., & Brismar, T. B. (2017) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2017.12.007 · Cited by 56
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 55
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma
Yoda, R. A., Marxen, T., Longo, L., Ene, C. I., Wirsching, H., Keene, C. D., Holland, E. C., & Cimino, P. J. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz082 · Cited by 55
Corell, A., Vega, S. F., Hoefling, N., Carstam, L., Smits, A., Bontell, T. O., Björkman‐Burtscher, I. M., Carén, H., & Jakola, A. S. (2020) · BMC Cancer · doi:10.1186/s12885-020-06951-w · Cited by 55
Quantification of aneuploidy in targeted sequencing data using ASCETS
Spurr, L. F., Touat, M., Taylor, A. M., Dubuc, A. M., Shih, J., Meredith, D. M., Pisano, W., Meyerson, M. M., Ligon, K. L., Cherniack, A. D., et al. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa980 · Cited by 54
Shen, C., Huang, B., Yeh, W., Chen, C., Liu, Y.-S., Lai, S., Tseng, W., Lu, D., & Tsai, C. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174216 · Cited by 54
Heng, J., & Heng, H. H. (2021) · Genes · doi:10.3390/genes13010101 · Cited by 55
Le, V. H., Minh, T. N. T., Kha, Q. H., & Le, N. Q. K. (2023) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-023-02875-2 · Cited by 54
Phillips, L. M., Zhou, X., Cogdell, D. E., Chua, C. Y. X., Huisinga, A., Hess, K. R., Fuller, G. N., & Zhang, W. (2016) · The Journal of Pathology · doi:10.1002/path.4734 · Cited by 54
Emerging targeted therapies for glioma
Miller, J. J., & Wen, P. Y. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1257609 · Cited by 55
Leblanc, V., Firme, M. R., Song, J., Chan, S. Y., Lee, M. H., Yip, S. S. F., Chittaranjan, S., & Marra, M. A. (2017) · The Journal of Pathology · doi:10.1002/path.4894 · Cited by 55
CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression
Mu, L., Yang, C., Gao, Q., Long, Y., Ge, H., DeLeon, G., Jin, L., Chang, Y. E., Sayour, E. J., Ji, J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01451 · Cited by 54
Liao, P., Ostrom, Q. T., Stetson, L. C., & Barnholtz‐Sloan, J. S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy003 · Cited by 54
Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics
Synhaeve, N. E., van den Bent, M. J., French, P. J., Dinjens, W. N. M., Atmodimedjo, P. N., Kros, J. M., Verdijk, R. M., Dirven, C. M. F., & Dubbink, H. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0633-y · Cited by 54
Chai, R., Zhang, K., Chang, Y., Wu, F., Liu, Y., Zhao, Z., Wang, K., Chang, Y., Jiang, T., & Wang, Y. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz102 · Cited by 55
Observing deep radiomics for the classification of glioma grades
Kobayashi, K., Miyake, M., Takahashi, M., & Hamamoto, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-90555-2 · Cited by 54
Lu, I., Dobersalske, C., Rauschenbach, L., Teuber‐Hanselmann, S., Steinbach, A., Ullrich, V., Prasad, S., Blau, T., Kebir, S., Siveke, J. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23995-z · Cited by 55
A prognostic signature of five pseudogenes for predicting lower-grade gliomas
Liu, B., Liu, J., Liu, K., Huang, H., Li, Y., Hu, X., Wang, K., Cao, H., & Cheng, Q. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109116 · Cited by 53
Genetic and epigenetic stability of oligodendrogliomas at recurrence
Aihara, K., Mukasa, A., Nagae, G., Nomura, M., Yamamoto, S., Ueda, H., Tatsuno, K., Shibahara, J., Takahashi, M., Momose, T., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0422-z · Cited by 55
Berntsson, S. G., Merrell, R. T., Amirian, E. S., Armstrong, G., Lachance, D. H., Smits, A., Zhou, R., Jacobs, D. I., Wrensch, M., Olson, S. H., et al. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8857-0 · Cited by 53
Neyra, M. A. T., Neuberger, U., Reinhardt, A., Brugnara, G., Bonekamp, D., Sill, M., Wick, A., Jones, D., Radbruch, A., Unterberg, A. W., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy134 · Cited by 53
Park, Y. W., Choi, Y. S., Ahn, S. S., Chang, J. H., Kim, S. H., & Lee, S. (2019) · Korean Journal of Radiology · doi:10.3348/kjr.2018.0814 · Cited by 53
Schön, S., Cabello, J., Liesche‐Starnecker, F., Molina‐Romero, M., Eichinger, P., Metz, M., Karimov, I., Preibisch, C., Keupp, J., Hock, A., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04677-x · Cited by 53
Investigation of Inter- and Intratumoral Heterogeneity of Glioblastoma Using TOF-SIMS
Gularyan, S. K., Gulin, A. A., Anufrieva, K. S., Shender, V. О., Shakhparonov, M. I., Bastola, S., Антипова, Н. В., Kovalenko, T. F., Rubtsov, Y. P., Latyshev, Y. A., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra120.001986 · Cited by 53
Lu, Y., Patel, M. D., Natarajan, K., Ughratdar, I., Sanghera, P., Jena, R., Watts, C., & Sawlani, V. (2020) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2020.09.017 · Cited by 53
Modeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors
Pasqualini, C., Kozaki, T., Bruschi, M., Nguyen, T. H. H., Minard‐Colin, V., Castel, D., Grill, J., & Ginhoux, F. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.018 · Cited by 55
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- Emory University (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2481-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4530011
- OpenAlex
- W1812256879
- Cited by
- 3,148
- References
- 54
- Citations by year
- 2026: 139 · 2025: 196 · 2024: 248 · 2023: 282 · 2022: 371 · 2021: 341 · 2020: 366 · 2019: 314 · 2018: 311 · 2017: 284 · 2016: 226 · 2015: 60
- FWCI
- 164.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, U54HG007990)
- National Cancer Institute (U24CA194362, U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, U24CA143858, U24CA126543, U24CA144025, U24CA126563, U01CA168394, U24CA143866, U24CA143883, U24CA143845, U24CA126544, R01CA163722, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA008748, P30CA016672, U24CA143731)
- National Institute of Neurological Disorders and Stroke (R01NS081125)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioma molecular subtypes, IDH mutation, 1p/19q codeletion, TP53 mutation, TERT promoter mutation, NOTCH1 mutation, CIC mutation, glioblastoma, prognostic factors, DNA methylation, DNA copy number, gene expression, microRNA expression
- MeSH terms
- Adolescent, Adult, Aged, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 19, DNA, Neoplasm, Female, Glioblastoma, Glioma, Humans, Male, Middle Aged, Mutation, Signal Transduction, Cluster Analysis, Proportional Hazards Models, Genes, p53, Sequence Analysis, DNA, Kaplan-Meier Estimate, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
